US biotech Novavax has initiated a pivotal two-stage study for its H1N1 influenza vaccine in Mexico. Novavax's strategy of pursuing approval for the vaccine in smaller markets before targeting the US represents an alternative and faster route to market. Given the many benefits of this strategy, Datamonitor believes that it may be adopted by other small vaccine companies in the future.
Edit my basket
© Datamonitor 2012. All rights reserved
Terms & Conditions